Patents by Inventor Wen-Ching Han

Wen-Ching Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
    Patent number: 8067582
    Abstract: Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: November 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, Ashvinikumar V. Gavai, James Aaron Balog, Joel F. Austin, Weifang Shan, Yufen Zhao, Andrew James Nation, Wen-Ching Han
  • PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20110039838
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: October 25, 2010
    Publication date: February 17, 2011
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION
    Publication number: 20100331324
    Abstract: Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: June 26, 2008
    Publication date: December 30, 2010
    Inventors: Derek J. Norris, Ashvinikumar V. Gavai, James Aaron Balog, Joel F. Austin, Weifang Shan, Yufen Zhao, Andrew James Nation, Wen-Ching Han
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7846931
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: December 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20090048244
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: September 24, 2008
    Publication date: February 19, 2009
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function
    Patent number: 7468439
    Abstract: Disclosed are sultam compounds of Formula (I) or a pharmaceutically-acceptable salt thereof. Also disclosed are methods of using such compounds in the treatment of at least one nuclear hormone receptor-associated condition, such as, for example, cancer and immune disorders, and at least one pharmaceutical composition comprising such compounds.
    Type: Grant
    Filed: September 5, 2007
    Date of Patent: December 23, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Weifang Shan, James Aaron Balog, Andrew James Nation, Ashvinikumar V. Gavai, Wen-Ching Han, Mark E. Salvati
  • Fused tricyclic compounds as inhibitors of 17?-hydroxysteroid dehydrogenase 3
    Patent number: 7417040
    Abstract: Disclosed are fused tricyclic compounds of the following formula I, or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof. The disclosed compounds are useful as inhibitors of 17?-hydroxysteriod dehydrogenase 3 (17?HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: August 26, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Wen-Ching Han, Raj N. Misra, Hai-Yun Xiao, Derek J. Norris, John S. Tokarski
  • Fused heterotricyclic compounds as inhibitors of 17?-hydroxysteroid dehydrogenase 3
    Patent number: 7378426
    Abstract: Disclosed are fused heterotricyclic compounds of the following formula I, or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of A ring or C ring is a 5-7 membered unsaturated heterocyclic ring. The disclosed compounds are useful as inhibitors of 17?-hydroxysteroid dehydrogenase 3 (17?-HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: May 27, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Derek J. Norris, Wen-Ching Han, Gregory D. Vite, Brian E. Fink, John S. Tokarski
  • ALKYLENE BRIDGED SULTAM COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION
    Publication number: 20080090883
    Abstract: Disclosed are sultam compounds of Formula (I) or a pharmaceutically-acceptable salt thereof. Also disclosed are methods of using such compounds in the treatment of at least one nuclear hormone receptor-associated condition, such as, for example, cancer and immune disorders, and at least one pharmaceutical composition comprising such compounds.
    Type: Application
    Filed: September 5, 2007
    Publication date: April 17, 2008
    Inventors: Weifang Shan, James Balog, Andrew Nation, Ashvinikumar Gavai, Wen-Ching Han, Mark Salvati
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7297695
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: November 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Pyrrolotriazine compounds
    Patent number: 7151176
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: December 19, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Wen-Ching Han, Yufen Zhao, Ping Chen
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7141571
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20060264438
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: June 26, 2006
    Publication date: November 23, 2006
    Applicant: Bristol-Myers Squibb Company
    Inventors: Brian Fink, Ashvinikumar Gavai, Gregory Vite, Ping Chen, Harold Mastalerz, Derek Norris, John Tokarski, Yufen Zhao, Wen-Ching Han
  • Di-substituted pyrrolotriazine compounds
    Patent number: 7064203
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: June 20, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Wen-Ching Han, Ping Chen, Edward H. Ruediger, Harold Mastalerz, Brian E. Fink, Derek J. Norris
  • Pyrrolotriazine compounds
    Publication number: 20060089358
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 27, 2006
    Inventors: Ashvinikumar Gavai, Wen-Ching Han, Yufen Zhao, Ping Chen
  • Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3
    Publication number: 20050250753
    Abstract: Fused tricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 25, 2005
    Publication date: November 10, 2005
    Inventors: Brian Fink, Ashvinikumar Gavai, Gregory Vite, Wen-Ching Han, Raj Misra, Hai-Yun Xiao, Derek Norris, John Tokarski
  • Di-substituted pyrrolotrizine compounds
    Publication number: 20050197339
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: December 22, 2004
    Publication date: September 8, 2005
    Inventors: Ashvinikumar Gavai, Wen-Ching Han, Ping Chen, Edward Ruediger, Harold Mastalerz, Brian Fink, Derek Norris
  • Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3
    Publication number: 20050192310
    Abstract: Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 1, 2005
    Inventors: Ashvinikumar Gavai, Derek Norris, Wen-Ching Han, Gregory Vite, Brian Fink, John Tokarski
  • Pyrrolotriazine compounds as kinase inhibitors
    Publication number: 20050182058
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: December 22, 2004
    Publication date: August 18, 2005
    Inventors: Brian Fink, Ashvinikumar Gavai, Gregory Vite, Ping Chen, Harold Mastalerz, Derek Norris, John Tokarski, Yufen Zhao, Wen-Ching Han
  • Aminothiazole inhibitors of cyclin dependent kinases
    Patent number: 6521759
    Abstract: The present invention describes compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, m and n are as defined in the specification. The compounds of formula I are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kyoung S. Kim, S. David Kimball, Zhen-wei Cai, David B. Rawlins, Raj N. Misra, Michael A. Poss, Kevin R. Webster, John T. Hunt, Wen-Ching Han